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Practice-changing radiation therapy trials for the treatment of
cancer: where are we 150 years after the birth of Marie Curie?
Mareike K. Thompson1, Philip Poortmans2, Anthony J. Chalmers3, Corinne Faivre-Finn4, Emma Hall5, Robert A. Huddart6,
Yolande Lievens7, David Sebag-Monteﬁore8 and Charlotte E. Coles9
As we mark 150 years since the birth of Marie Curie, we reﬂect on the global advances made in radiation oncology and the current
status of radiation therapy (RT) research. Large-scale international RT clinical trials have been fundamental in driving evidence-
based change and have served to improve cancer management and to reduce side effects. Radiation therapy trials have also
improved practice by increasing quality assurance and consistency in treatment protocols across multiple centres. This review
summarises some of the key RT practice-changing clinical trials over the last two decades, in four common cancer sites for which RT
is a crucial component of curative treatment: breast, lung, urological and lower gastro-intestinal cancer. We highlight the global
inequality in access to RT, and the work of international organisations, such as the International Atomic Energy Agency (IAEA), the
European SocieTy for Radiotherapy and Oncology (ESTRO), and the United Kingdom National Cancer Research Institute Clinical and
Translational Radiotherapy Research Working Group (CTRad), that aim to improve access to RT and facilitate radiation research. We
discuss some emerging RT technologies including proton beam therapy and magnetic resonance linear accelerators and predict
likely future directions in clinical RT research.
British Journal of Cancer https://doi.org/10.1038/s41416-018-0201-z
INTRODUCTION
Born Maria Salomea Skłodowska on 7 November 1867 in Warsaw,
Poland, Marie Curie later went on to discover both polonium and
radium, and won two Nobel prizes for her work on radioactive
substances. Later, during the First World War, she set up a ﬂeet of
mobile X-ray units, popularly called ‘the little Curies’, to enable
military doctors to locate and remove shrapnel from soldiers’
wounds at the front line. After the war, she was instrumental in
founding the Institut du Radium in Paris, which later became part
of the Institut Curie, now a world-leading oncology research
centre. To mark the 150th anniversary of her birth, we reﬂect on
the global advances made in radiation oncology, focussing on
radiation therapy (RT) practice-changing trials over the last two
decades. In addition, we discuss global inequalities in access to RT
and highlight possible future directions of clinical RT research.
RT IS A CRUCIAL AND COST-EFFECTIVE CANCER TREATMENT
Systemic therapy may mistakenly be considered the mainstay of
curative oncological treatment, perhaps due to its high proﬁle in
the media. In fact, 40% of patients who are cured of cancer will
receive RT as part of their management, and around 50% of
cancer patients will require RT at some point during
their treatment in high as well as low and middle-income
countries.1–4 Despite representing a large proportion of cancer
treatment, RT accounts for only 5% of the national cancer budget
in both the UK and Sweden.3,5 By contrast, the European Union
average proportion of total oncology expenditure spent on cancer
drugs has increased from 12% in 2005 to 23% in 2014.6 In addition
to its curative potential, RT also has a key role in the palliation of
symptoms including pain, bleeding and nerve compression, as
well as in curative intent treatments.
RT comprises multiple different treatment modalities, including
external beam therapy (encompassing photons, electrons, protons
and other particles) and internal/surface treatment (brachytherapy
and radiopharmaceuticals). The most widely used modality is
megavoltage photon therapy, which is a form of high-energy
electromagnetic radiation produced by a linear accelerator.
Megavoltage photons have a range of tissue penetration, which
allows treatment of deeper internal body structures, such as pelvic
organs and lung tumours. Other forms of external beam therapy
are orthovoltage photons, which have shallower tissue penetra-
tion and are useful for treating skin and soft tissue; and electrons,
which also have a short range of tissue penetration but a different
dose distribution to orthovoltage photons, and are used mainly
for treating skin and superﬁcial tumours. Proton beam therapy is
an emerging form of external beam therapy, which has a peak of
dose deposition at a sharply deﬁned point (the ‘Bragg peak’) and
as such has potential for a much lower dose to nearby critical
organs. Internal RT uses very short-range radiation from
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radioactive sources delivered inside the body. This can be solid
sources placed during a surgical procedure or on the body surface,
as in brachytherapy for prostate or cervical cancer. Alternatively,
unsealed sources may be used, for example radiopharmaceutical
injections, which are preferentially taken up by cancer tissues.
RT has dramatically improved both technologically and in terms
of clinical outcomes; less than two decades ago, RT was mostly
given as simple ‘ﬁelds’, which are square/rectangular beams, with
minimal imaging guidance. Now, it is increasingly common to
deliver highly targeted image-guided treatment with intensity
modulated RT (IMRT). This enables dose reduction to the
surrounding normal structures, thereby minimising toxicity, and
facilitates dose escalation to the tumour, thereby maximising
cancer control.7,8 Another new technique is stereotactic body RT
(SBRT), which allows the administration of very high doses of
precision radiation in a small number of treatments (fractions).9
This is currently used for some primary lung and brain tumours,
but also raises the tantalising question of whether patients with a
limited number of metastases (‘oligometastatic disease’) could
also be cured using this new technology, in combination with
systemic therapy. Finally, the mechanistic understanding of how
RT interacts with cancerous and normal tissue at a cellular and
molecular level is moving at a rapid pace; as a result, exciting
opportunities are now arising for investigating RT in combination
with novel drugs, such as immunotherapy and DNA damage
response inhibitors10,11 (Fig. 1).
RT practice has historically varied greatly across international
and national institutions, and even within individual centres. Over
recent years, a growing focus on evidence-based medicine has led
to an increasing number of RT clinical trials that aim to improve
patient outcomes by improving overall survival and local tumour
control, and/or reducing (often permanent) side effects. Second-
ary but important beneﬁts of these practice-changing clinical trials
include improvements in RT quality and consistency across
multiple centres. This manuscript aims to highlight to a non-
specialist audience the results from a number of key clinical trials
in RT research. An international range of expert authors selected
trials for inclusion that have changed clinical practice by
inﬂuencing national or international guidelines. Selected trials
were published in the last 20 years in four common cancer types
where RT is a key component of curative intent treatment: breast,
lung, urological and lower gastrointestinal. The majority of the
included trials were large randomised phase 3 trials. Explanation
of some technical terms is included in Box 1 to assist the non-
specialist reader.
The collective effect of these clinical trials is that much of the
treatment of patients with RT is now based on prospective clinical
trial data of efﬁcacy and toxicity rather than historical and
empirical practice. There remains, however, considerable progress
to be made in further improving outcomes for patients, by
ensuring that existing clinical trial evidence is translated into
global clinical practice, and by instigating further research into
novel technologies and drug–RT combinations.
BREAST RT PRACTICE-CHANGING TRIALS
The Early Breast Cancer Trialists’ Collaborative group has clearly
demonstrated, through their individual patient-data meta-ana-
lyses from randomised clinical trials (RCTs), that RT improves local
control and survival following breast-conserving surgery, or
following mastectomy for node-positive tumours.12,13 The RCTs
included in this meta-analysis generally span several decades, with
the earliest commencing in 1964 and all trials starting before 2000.
More recent practice-changing trials (Table 1) have investigated
the use of fewer treatments (hypofractionation), the role of
tumour bed boost, partial breast irradiation, and nodal irradiation.
Hypofractionation, boost and partial breast RT
Evidence from more than 7000 women treated and followed up
for 10 years within the UK START and Canadian RCTs
demonstrated that shorter, hypofractionated courses of RT are
non-inferior to 5 weeks of ‘conventionally’ fractionated therapy
(25 fractions) for local tumour control. Furthermore, these
hypofractionated treatments cause not more (Canadian fractio-
nation schedule: 16 fractions of 2.66 Gy) or even fewer (UK
fractionation schedule: 15 fractions of 2.67 Gy) late side
effects14–16 than the conventional regimens. This confers
important beneﬁts, since late RT toxicity tends to be perma-
nent.17 In addition, fewer RT visits are more convenient for
patients and more cost-effective for healthcare providers.18–20
These results led to hypofractionation being adopted within
international guidelines from the American Society for Radiation
Oncology (ASTRO) and the UK National Institute for Health and
Care Excellence (NICE).21,22 While hypofractionation is now
standard practice in the UK and widely adopted in Canada,
uptake in the United States and Europe is patchy, despite the
convincing evidence. This is perceived to be a consequence of
professional and societal barriers to optimal care, together with
variations in treatment economics across different healthcare
systems and speciﬁcally reimbursement, which is still calculated
per fraction in many countries.23,24
The EORTC 22881-10882 study randomised patients to receive
either a boost dose to the tumour bed following whole-breast
irradiation, or whole-breast irradiation alone. This trial showed
improved local control in patients receiving the boost, although
this was at the cost of increased late side effects.25,26 After long-
term updates, which conﬁrmed the results and enabled better
subgroup analyses, this trial led to international guidelines widely
recommending a boost for patients ‘at high risk of recurrence’
following breast conserving surgery, but advising that the boost
could be safely avoided for those at low/intermediate risk.21,22
The aim of partial irradiation is to focus RT on the region at
highest risk of recurrence, to maintain high rates of local tumour
control while minimising toxicity by virtue of a smaller irradiated
volume. Very promising results were demonstrated by the
Budapest and Florence partial breast RT trials, but the relatively
small numbers in these studies have been insufﬁcient to change
practice internationally.27,28 Intra-operative partial breast RT has
also been investigated and is potentially very attractive to patients
if it means post-operative RT can be avoided. However, the ELIOT
trial using intra-operative electrons failed to show non-inferiority
with whole-breast RT; this may have been at least in part due to
patient selection due to inclusion of patients with higher risk of
recurrence.29 The TARGIT trial using photon intra-operative RT
reported non-inferiority with whole-breast RT, but non-standard
statistical analysis was used and median follow up was very short
at only 2 years 5 months.30,31 Two large randomised partial breast
RT trials have recently reported: IMPORT LOW and GEC-ESTRO.32,33
IMPORT LOW reported that partial breast RT, delivered over an
identical 3-week period to the control group, yielded non-
inferiority in local relapse rates while also reducing side effects.
These results have been published too recently to be labelled
‘practice changing’; however, the study marked an important step
in reducing late toxicity for a large population of low-risk patients.
IMPORT LOW also used a simple RT technique leveraging existing
radiotherapy equipment and standard RT techniques, with the
only difference being the reduced treatment volume. The GEC-
ESTRO trial, which used a brachytherapy approach for accelerated
partial breast irradiation, conﬁrmed non-inferiority with whole-
breast RT. The results of four further phase 3 RCTs investigating
partial breast RT using different techniques will be published in
the next few years (NCT00103181, NCT00282035, NCT01247233,
NCT01803958).
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Nodal irradiation
Some breast cancer recurrences occur locoregionally and
therefore the local management of local lymph node groups is
an important consideration, especially in patients at higher risk
of recurrence. The AMAROS trial randomised patients to either
surgical dissection or axillary node RT, following positive
sentinel lymph node biopsy, and reported reduced rates of
lymphoedema in the RT arm with comparable loco-regional
tumour control rates. This important study provides patients
with more options after a positive sentinel lymph node biopsy,
and has led to a dramatic fall in axillary surgery in many
centres.34 More recently, there has been increasing interest in
the addition of internal mammary chain (IMC) nodal irradiation
to standard RT. Two large RCTs were published in 2015, both of
which showed an improvement in disease-free survival with the
addition of IMC irradiation.35,36 This was conﬁrmed in a
population-based Danish study where patients with right-sided
breast cancer received IMC-RT, whereas left-sided patients did
not and received normal standard of care at the time.37 These
studies led to IMC irradiation being re-introduced in the 2016
ASCO post-mastectomy RT guidelines.38
Taken together, these practice-changing trials have facilitated
‘risk-adapted RT’, whereby breast RT approaches are offered
based on the individual’s broad risk of recurrence. These range
from partial breast RT in lower risk patients to IMC RT in high-risk
patients in order to optimise local tumour control while
minimising side effects. This demonstrates that RT for breast
cancer is no longer a ‘one size ﬁts all’ strategy, although we are
still some way from delivering truly personalised breast RT.
Further research is needed to: reliably identify which group of
patients can avoid breast RT completely39; determine optimal
timing of RT with mastectomy and reconstruction40; determine
whether there is an advantage to deliver breast RT pre-
operatively and how to best combine RT with novel drugs in
higher risk patients.41
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Fig. 1 RT has great potential to be combined with multiple classes of novel drugs. Reprinted from Nature Reviews Clinical Oncology.11
Box 1 Common radiotherapy terminology
Brachytherapy: The delivery of radioactive material very close to or within a
patient’s tumour to provide high doses of radiation at a short distance.
Brachytherapy is also known as sealed source therapy.
Electrons: Treatment using an electron beam, usually for skin tumours or
superﬁcial tumours.
External beam therapy: All types of radiation therapy delivered from outside
the patient; includes photons, protons and electrons.
Fraction: Radiation therapy is typically split into multiple treatments, known as
fractions. These are often given daily over several weeks to enable a tumouricidal
dose to be given whilst allowing time for normal tissue recovery.
Hypofractionation: Treatment involving a decreased number of fractions of
increased fraction size (>2 Gy per fraction).
Hyperfractionation: Treatment involving an increased number of fractions of
reduced fraction size (<2 Gy per fraction).
Image-guided RT (IGRT): Any radiation therapy that includes imaging pre-
treatment or during delivery to improve the accuracy of radiotherapy.
Intensity modulated radiotherapy (IMRT): A precise form of radiation therapy
using multiple small ﬁelds to closely conform the dose of radiation to the tumour.
Molecular radiotherapy: The delivery of radiation to a cancer using radio-
pharmaceuticals which interact with molecular sites or receptors, for example
Radium-223.
Photons: High-energy X-ray treatment; comprises the majority of radiation
treatment.
Proton beam radiotherapy: Treatment using a proton beam.
Stereotactic ablative RT, stereotactic body RT (SABR, SBRT): Highly precise
irradiation of an extra-cranial lesion using a high dose of radiation in a small
number of fractions.
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LUNG RT PRACTICE-CHANGING TRIALS
In recent years we have seen many technological advances in the
ﬁeld of lung radiotherapy. These include the integration of 4-
dimensional computed tomography (CT) and positron emission
tomography (PET) for planning; the improved target conformality
with the delivery of IMRT; SBRT; and the optimisation of image
guidance (Table 2).
Early-stage non-small cell lung cancer
A key change in lung RT has been the introduction of SBRT for
early-stage non-small cell lung cancers (NSCLC). This development
came after multiple studies investigated this highly targeted and
high-dose RT, which is delivered in just a few fractions. Treatment
outcomes are comparable with surgery, especially for patients
with medical co-morbidities.42–51 Evidence-based guidelines,
mostly based on non-randomised phase II trials, distinguish
patients who can be treated safely with SBRT from those at risk
of excessive toxicity (especially those with centrally located
tumours). Patients at higher risk of toxicity should be treated
with a dose-adapted SBRT regimen, preferably within further
clinical trials to allow collection of high-quality prospective toxicity
data.52 Population-based studies have also demonstrated the
effectiveness of this technique for improving overall survival in a
non-selected elderly patient population.53,54
Locally advanced NSCLC
One of the main strategies for improving outcomes in patients
with locally advanced NSCLC is dose escalation, which has shown
encouraging results in phase I–II trials over the last two
decades.55–58 However, the outcome of the phase III Radiation
Therapy Oncology Group (RTOG) 0617 trial was surprisingly
disappointing;59 dose escalation with concurrent chemoradiother-
apy to 74 Gy in 37 fractions led to worse survival, compared with
the standard of care (60 Gy in 30 fractions). The results of RTOG
0617 had a profound impact on usual clinical practice and future
clinical trials, establishing 60 Gy in 30 fractions as the new
benchmark for chemoradiotherapy in locally advanced NSCLC.
Importantly, it also provided prospective evidence supporting
IMRT for NSCLC, as a secondary analysis showed IMRT produced
lower rates of severe pneumonitis and resulted in lower cardiac
doses, compared with conventional RT.60
NSCLC and brain metastases
Avoidance of unnecessary treatment is important, especially for
patients requiring palliation. The QUARTZ trial examined the role
of whole-brain RT (WBRT) plus optimal supportive care in patients
with NSCLC and brain metastases. The trial found no improvement
in survival or quality adjusted life years with the addition of
WBRT.61 As a result, WBRT is usually not recommended for the
majority of patients; however, it may still be beneﬁcial for some
patients with better prognosis, such as those with driver
mutations.
Small cell lung cancer
Very little progress was made for several decades in the systemic
treatment of both limited- and extensive-stage small cell lung
cancer (SCLC). Recently, advances in RT techniques, use of
prophylactic cranial irradiation for all stages of SCLC, and improved
combination of chemotherapy with RT have led to major
improvements in survival. The current standard of care for patients
with limited-stage SCLC is based on an RCT that compared once
daily with twice-daily RT delivered concurrently with chemotherapy,
which demonstrated superiority of twice-daily RT in terms of
survival.62 However, since the publication of this study in 1999, there
has been a lack of consensus regarding routine use of twice-daily RT,
despite its superiority, due to logistical issues and concerns
regarding toxicity (for example, one-third of the patients developed
≥grade 3 radiation oesophagitis). To help resolve this, the CONVERTT
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trial compared twice-daily RT (45 Gy in 30 fractions) to a higher RT
dose delivered once daily (66 Gy in 33 fractions), both given
concurrently with chemotherapy.63 Overall survival outcomes did
not differ between the two groups; however, the survival achieved
in both groups was higher and toxicity much lower (>50%
reduction) than previously reported.62 As this trial was designed to
show superiority of once-daily RT and was not powered to show
equivalence, the implication is that twice-daily RT should be
considered the standard of care.
In the extensive-stage setting, an EORTC trial demonstrated that
prophylactic cranial irradiation in patients who had responded to
chemotherapy reduced the incidence of brain metastases and
improved survival, compared with no subsequent treatment.64
Later, the CREST trial randomised extensive-stage SCLC patients to
receive either thoracic RT (30 Gy in ten fractions) and prophylactic
cranial irradiation, or to receive prophylactic cranial irradiation
alone. Although there was no difference in overall survival at 1
year, a pre-planned analysis revealed a signiﬁcant improvement in
overall survival at 2 years, with a low rate of severe toxicities.65
Both of these trials were practice changing, and have led to new
recommendations in international guidelines.66
The studies discussed have demonstrated signiﬁcant survival
improvements in both NSCLC and SCLC patients. Areas of unmet
research need include the evaluation of modern RT technologies
(such as SBRT and protons) in a wider population, and the
development of individualised treatment strategies.
UROLOGICAL RT PRACTICE-CHANGING TRIALS
Radiation-based therapy is used as an alternative to radical
prostatectomy for localised disease, producing equivalent survival
to surgery.67 It is also used as the key treatment modality for
locally advanced disease. The development of RT as a curative
treatment has been supported by technical reﬁnement of RT,
including treatment delivery with reduced toxicity, dose escalation
and use of concomitant androgen deprivation therapy (ADT)
(Table 3).
Localised prostate cancer
RCTs have led to a signiﬁcant improvement in the evidence base
supporting RT for localised prostate cancer over the last two
decades. Prior to this, clinical practice was largely based on non-
randomised studies. Recognition of the beneﬁt for local control,
even in high-risk/locally advanced patients, has been of key
importance. The PR07 trial in locally advanced or ‘high risk’
localised node-negative prostate cancer provided evidence for a
clear survival beneﬁt of RT in addition to ADT, and similar results
were reported by a Scandinavian trial.68,69 Non-randomised data
from the STAMPEDE RCT also showed signiﬁcantly improved
survival with combined RT and ADT, compared with ADT alone, in
patients with both high-risk and node-positive prostate cancer.70
Furthermore, several randomised dose-escalation studies have
provided evidence to support an increased RT dose from 64–68 Gy
to 74–78 Gy.71–73 These dose escalation trials showed improve-
ments in biochemical progression-free survival, but not overall
survival. The addition of RT to ADT, and use of a higher dose range
74–78 Gy, are now routine practice in the UK. Recent data suggest
that additional beneﬁt could be accrued through further dose
escalation using a brachytherapy boost in high-risk patients, at the
cost of increased toxicity.74
Based on the principle that prostate cancer may be more
sensitive to increases in daily dose per fraction than previously
thought, the CHHiP trial compared two hypofractionated regi-
mens (60 Gy in 20 fractions vs. 57 Gy in 19 fractions) to the
standard UK regimen at the time (74 Gy in 37 fractions), in men
with T1b–T3aN0M0 prostate cancer. The 5-year results demon-
strated that 60 Gy in 20 fractions was non-inferior to the standard
regimen in terms of biochemical or clinical failure, and wasT
ab
le
2
co
nt
in
ue
d
Tr
ia
l
n
am
e
(ﬁ
rs
t
au
th
o
r)
Tr
ia
l
m
et
h
o
d
o
lo
g
y
Pr
ac
ti
ce
-d
eﬁ
n
in
g
tr
ia
l
re
su
lt
s
an
d
m
et
h
o
d
s
Pu
b
lic
at
io
n
s
o
f
tr
ia
l
re
su
lt
s
Pu
b
lic
at
io
n
s
re
la
te
d
to
tr
ia
l
co
n
d
u
ct
Ev
id
en
ce
o
f
p
ra
ct
ic
e
ch
an
g
e
Ex
te
n
si
ve
-s
ta
g
e
sm
al
l
ce
ll
lu
n
g
ca
n
ce
r
EO
R
TC
p
ro
p
h
yl
ac
ti
c
cr
an
ia
l
ir
ra
d
ia
ti
o
n
tr
ia
l
(S
lo
tm
an
)
Ph
as
e
3.
R
an
d
o
m
is
ed
28
6
p
at
ie
n
ts
to
PC
I
vs
.n
o
fu
rt
h
er
tr
ea
tm
en
t
in
p
at
ie
n
ts
w
it
h
ex
te
n
si
ve
sm
al
lc
el
ll
u
n
g
ca
n
ce
r
w
h
o
h
ad
re
sp
o
n
d
ed
to
ch
em
o
th
er
ap
y.
Si
g
n
iﬁ
ca
n
t
im
p
ro
ve
m
en
t
in
m
ed
ia
n
o
ve
ra
ll
su
rv
iv
al
w
it
h
PC
I,
as
w
el
l
as
a
lo
w
er
cu
m
u
la
ti
ve
ri
sk
o
f
b
ra
in
m
et
as
ta
se
s
at
1
ye
ar
.
6
4
1
7
5
In
te
rn
at
io
n
al
:E
SM
O
.6
6
N
C
C
N
.1
7
0
C
R
ES
T
(S
lo
tm
an
)
Ph
as
e
3.
R
an
d
o
m
is
ed
49
8
p
at
ie
n
ts
to
th
o
ra
ci
c
ra
d
io
th
er
ap
y
30
G
y
in
te
n
fr
ac
ti
o
n
s
vs
.n
o
th
o
ra
ci
c
ra
d
io
th
er
ap
y,
in
p
at
ie
n
ts
w
it
h
ex
te
n
si
ve
-s
ta
g
e
sm
al
l
ce
ll
lu
n
g
ca
n
ce
r
w
h
o
h
ad
re
sp
o
n
d
ed
to
ch
em
o
th
er
ap
y.
N
o
si
g
n
iﬁ
ca
n
t
d
iff
er
en
ce
in
1-
ye
ar
su
rv
iv
al
(p
ri
m
ar
y
en
d
p
o
in
t)
.S
ig
n
iﬁ
ca
n
t
im
p
ro
ve
m
en
t
in
o
ve
ra
ll
su
rv
iv
al
at
2
ye
ar
s
w
it
h
th
o
ra
ci
c
ra
d
io
th
er
ap
y,
w
it
h
n
o
in
cr
ea
se
in
se
ve
re
(g
ra
d
e
3
o
r
h
ig
h
er
)
to
xi
ci
ty
.
6
5
,1
7
6
1
7
7
,1
7
8
In
te
rn
at
io
n
al
:S
u
rv
ey
o
f
Eu
ro
p
ea
n
ce
n
tr
es
:
81
%
n
o
w
g
iv
in
g
th
o
ra
ci
c
R
T
in
ES
-S
C
LC
co
m
p
ar
ed
to
25
%
p
re
vi
o
u
sl
y.
1
7
7
N
C
C
N
.1
7
0
ES
M
O
Eu
ro
p
ea
n
So
ci
et
y
fo
r
M
ed
ic
al
O
n
co
lo
g
y,
N
CC
N
N
at
io
n
al
C
o
m
p
re
h
en
si
ve
C
an
ce
r
N
et
w
o
rk
Practice-changing radiation therapy trials…
MK Thompson et al.
7
Ta
bl
e
3.
Su
m
m
ar
y
o
f
u
ro
lo
g
ic
al
ca
n
ce
r
p
ra
ct
ic
e-
d
eﬁ
n
in
g
R
T
cl
in
ic
al
tr
ia
ls
Tr
ia
l
n
am
e
(ﬁ
rs
t
au
th
o
r)
Tr
ia
l
m
et
h
o
d
o
lo
g
y
Pr
ac
ti
ce
-d
eﬁ
n
in
g
tr
ia
l
re
su
lt
s
an
d
m
et
h
o
d
s
Pu
b
lic
at
io
n
s
o
f
tr
ia
l
re
su
lt
s
Pu
b
lic
at
io
n
s
re
la
te
d
to
tr
ia
l
co
n
d
u
ct
Ev
id
en
ce
o
f
p
ra
ct
ic
e
ch
an
g
e
Pr
o
st
at
e
PR
-0
7
(M
as
o
n
)
A
n
d
ro
g
en
d
ep
ri
va
ti
o
n
th
er
ap
y
(A
D
T
)
al
o
n
e
vs
.A
D
T
+
R
T
in
m
en
w
it
h
T3
-4
N
0M
0
p
ro
st
at
e
ca
n
ce
r,
o
r
T1
-2
d
is
ea
se
w
it
h
PS
A
>
40
o
r
PS
A
20
–
40
w
it
h
G
le
as
o
n
sc
o
re
8–
10
.
R
an
d
o
m
is
ed
12
05
p
at
ie
n
ts
.
O
ve
ra
ll
su
rv
iv
al
si
g
n
iﬁ
ca
n
tl
y
im
p
ro
ve
d
b
y
th
e
ad
d
it
io
n
o
f
R
T.
6
9
N
A
U
K
:N
IC
E.
1
7
9
SP
C
G
-7
(W
id
m
ar
k)
A
D
T
al
o
n
e
vs
.A
D
T
+
R
T.
R
an
d
o
m
is
ed
87
5
p
at
ie
n
ts
.
A
d
d
it
io
n
o
f
R
T
im
p
ro
ve
d
o
ve
ra
ll
su
rv
iv
al
an
d
p
ro
st
at
e
ca
n
ce
r
sp
ec
iﬁ
c
m
o
rt
al
it
y.
6
8
N
A
U
K
:N
IC
E.
1
7
9
M
R
C
R
T-
01
(D
ea
rn
al
ey
)
R
ad
ic
al
R
T
64
G
y
in
32
fr
ac
ti
o
n
s
vs
.7
4
G
y
in
37
fr
ac
ti
o
n
s.
R
an
d
o
m
is
ed
84
3
p
at
ie
n
ts
.
Si
g
n
iﬁ
ca
n
tl
y
im
p
ro
ve
d
b
io
ch
em
ic
al
p
ro
g
re
ss
io
n
-f
re
e
su
rv
iv
al
in
th
e
74
G
y
d
o
se
g
ro
u
p
,b
u
t
n
o
im
p
ro
ve
m
en
t
in
o
ve
ra
ll
su
rv
iv
al
.
7
2
,7
3
1
8
0
In
te
rn
at
io
n
al
:N
C
C
N
.1
8
1
U
K
:N
IC
E.
1
7
9
D
u
tc
h
(P
ee
te
rs
)
78
G
y
vs
.6
8
G
y
in
p
at
ie
n
ts
w
it
h
T1
-4
p
ro
st
at
e
ca
n
ce
r
w
it
h
PS
A
<
60
.R
an
d
o
m
is
ed
66
9
p
at
ie
n
ts
.
Si
g
n
iﬁ
ca
n
tl
y
im
p
ro
ve
d
b
io
ch
em
ic
al
p
ro
g
re
ss
io
n
-f
re
e
su
rv
iv
al
fo
r
78
G
y
b
u
t
n
o
ef
fe
ct
o
n
o
ve
ra
ll
su
rv
iv
al
.H
ig
h
er
ra
te
s
o
f
ac
u
te
an
d
la
te
G
I
an
d
G
U
to
xi
ci
ty
fo
r
78
G
y
g
ro
u
p
.
7
1
,1
8
2
N
A
In
te
rn
at
io
n
al
:N
C
C
N
.1
8
1
U
K
:N
IC
E.
1
7
9
R
TO
G
04
15
(L
ee
)
73
.8
G
y
in
41
fr
ac
ti
o
n
s
vs
.a
h
yp
o
fr
ac
ti
o
n
at
ed
re
g
im
e
70
G
y
in
28
fr
ac
ti
o
n
s
fo
r
m
en
w
it
h
lo
w
-r
is
k
p
ro
st
at
e
ca
n
ce
r.
R
an
d
o
m
is
ed
10
92
p
at
ie
n
ts
.
H
yp
o
fr
ac
ti
o
n
at
ed
re
g
im
e
n
o
n
-in
fe
ri
o
r
to
co
n
ve
n
ti
o
n
al
fr
ac
ti
o
n
at
io
n
,b
u
t
re
su
lt
ed
in
si
g
n
iﬁ
ca
n
tl
y
in
cr
ea
se
d
la
te
g
ra
d
e
2/
3
G
I
an
d
G
U
to
xi
ci
ty
.
8
0
N
A
N
A
H
Y
PR
O
(A
lu
w
in
i)
H
yp
o
fr
ac
ti
o
n
at
ed
R
T
o
f
64
·6
G
y
in
19
fr
ac
ti
o
n
s,
th
re
e
fr
ac
ti
o
n
s
p
er
w
ee
k
vs
.7
8
G
y
in
39
fr
ac
ti
o
n
s,
ﬁ
ve
fr
ac
ti
o
n
s
p
er
w
ee
k,
in
m
en
w
it
h
in
te
rm
ed
ia
te
-h
ig
h
-r
is
k
p
ro
st
at
e
ca
n
ce
r.
R
an
d
o
m
is
ed
80
4
p
at
ie
n
ts
.
H
yp
o
fr
ac
ti
o
n
at
ed
re
g
im
e
w
as
n
o
t
su
p
er
io
r
to
th
e
co
n
ve
n
ti
o
n
al
ly
fr
ac
ti
o
n
at
ed
re
g
im
e
in
te
rm
s
o
f
5-
ye
ar
re
la
p
se
-f
re
e
su
rv
iv
al
,w
it
h
h
ig
h
er
in
ci
d
en
ce
o
f
ac
u
te
G
I
to
xi
ci
ty
,l
at
e
G
I
an
d
la
te
G
U
to
xi
ci
ty
.
7
9
,1
8
3
,1
8
4
N
A
N
A
C
H
H
iP
(D
ea
rn
al
ey
)
60
G
y
in
20
fr
ac
ti
o
n
s
O
R
57
G
y
in
19
fr
ac
ti
o
n
s)
vs
.s
ta
n
d
ar
d
d
o
se
74
G
y
in
37
fr
ac
ti
o
n
s
fo
r
ra
d
ic
al
tr
ea
tm
en
t
o
f
T1
-3
aN
0M
0
p
ro
st
at
e
ca
n
ce
r
w
it
h
PS
A
<
30
.R
an
d
o
m
is
ed
32
16
p
at
ie
n
ts
.
60
G
y
in
20
fr
ac
ti
o
n
s
o
ve
r
4
w
ee
ks
n
o
n
-
in
fe
ri
o
r
to
co
n
ve
n
ti
o
n
al
ly
fr
ac
ti
o
n
at
ed
ra
d
io
th
er
ap
y,
w
it
h
si
m
ila
r
ra
te
s
o
f
to
xi
ci
ty
.
D
o
se
co
n
st
ra
in
ts
d
es
ig
n
ed
fo
r
th
e
C
H
H
iP
tr
ia
l
ad
o
p
te
d
in
o
th
er
tr
ia
ls
.S
u
p
p
o
rt
ed
im
p
le
m
en
ta
ti
o
n
o
f
IM
R
T
fo
r
p
ro
st
at
e
ca
n
ce
r
tr
ea
tm
en
t.
7
5
,7
6
N
A
In
te
rn
at
io
n
al
:A
U
A
/A
ST
R
O
/S
U
O
:
g
u
id
el
in
e.
1
8
5
G
er
m
an
So
ci
et
y
o
f
R
ad
ia
ti
o
n
O
n
co
lo
g
y
g
u
id
el
in
e.
1
8
6
U
K
:R
C
R
d
o
se
fr
ac
ti
o
n
at
io
n
g
u
id
el
in
e.
7
7
PR
O
FI
T
(C
at
to
n
)
78
G
y
in
39
fr
ac
ti
o
n
s
vs
.h
yp
o
fr
ac
ti
o
n
at
ed
R
T
o
f
60
G
y
in
20
fr
ac
ti
o
n
s
o
ve
r
4
w
ee
ks
,w
it
h
b
o
th
ar
m
s
re
ce
iv
in
g
n
o
A
D
T.
R
an
d
o
m
is
ed
12
06
m
en
.
N
o
n
-in
fe
ri
o
r
b
io
ch
em
ic
al
-c
lin
ic
al
fa
ilu
re
fo
r
h
yp
o
fr
ac
ti
o
n
at
io
n
w
it
h
n
o
in
cr
ea
se
in
g
ra
d
e
3
o
r
h
ig
h
er
la
te
G
I
o
r
G
U
to
xi
ci
ty
.
8
1
N
A
In
te
rn
at
io
n
al
:A
U
A
/A
ST
R
O
/S
U
O
:
g
u
id
el
in
e.
1
8
5
G
er
m
an
So
ci
et
y
o
f
R
ad
ia
ti
o
n
O
n
co
lo
g
y
g
u
id
el
in
e.
1
8
6
U
K
:R
C
R
d
o
se
fr
ac
ti
o
n
at
io
n
g
u
id
el
in
e.
7
7
A
LS
Y
M
PC
A
(P
ar
ke
r)
R
ad
iu
m
-2
23
vs
.p
la
ce
b
o
in
m
en
w
it
h
ca
st
ra
ti
o
n
-r
es
is
ta
n
t
p
ro
st
at
e
ca
n
ce
r
an
d
b
o
n
e
m
et
as
ta
se
s,
g
iv
en
4
w
ee
kl
y
fo
r
a
to
ta
l
o
f
6
in
je
ct
io
n
s.
R
an
d
o
m
is
ed
92
1
p
at
ie
n
ts
in
a
2:
1
ra
ti
o.
Im
p
ro
ve
d
o
ve
ra
ll
su
rv
iv
al
fo
r
ra
d
iu
m
-2
23
,
w
it
h
lo
n
g
er
ti
m
e
to
ﬁ
rs
t
sy
m
p
to
m
at
ic
sk
el
et
al
re
la
te
d
ev
en
t
an
d
im
p
ro
ve
d
q
u
al
it
y
o
f
lif
e
sc
o
re
s
in
th
e
ra
d
iu
m
g
ro
u
p
.
8
2
,8
3
,1
8
7
N
A
In
te
rn
at
io
n
al
:E
SM
O
.8
4
N
C
C
N
.1
8
1
U
K
:N
IC
E.
8
5
Practice-changing radiation therapy trials…
MK Thompson et al.
8
associated with similar toxicity.75,76 As a result, this trial has
already changed practice in the majority of UK centres.77,78 The
RTOG 0415, HYPRO and PROFIT trials have also recently published
data supporting the use of moderate hypofractionation; it seems
likely that these trials together will lead to wider international use
of hypofractionation in low-intermediate-risk prostate cancer.79–81
Metastatic prostate cancer
The most common metastatic site in prostate cancer is bone.
Delivery of RT to multiple sites of bone disease can be achieved by
using bone-seeking radiopharmaceuticals. Beta-emitting radio-
isotopes such as strontium-89 have been used in the palliation of
bone pain for many years. More recently the alpha-emitting
radioisotope radium-223, given as a course of 6-monthly
injections, has been shown to be a key addition to the treatment
options for men with castration-resistant prostate cancer with
bone metastases. The ALSYMPCA trial clearly demonstrated an
improvement in overall survival, quality of life scores, and time to
ﬁrst symptomatic skeletal-related event for radium-223, when
compared with placebo.82,83 This treatment has been rapidly
included in international guidelines and clinical practice, and
provides another important addition to treatment options for men
with castration-resistant prostate cancer.84,85
Muscle-invasive bladder cancer
RT has been used as an alternative bladder-preserving modality to
radical cystectomy for muscle-invasive bladder cancer, but has
been limited by the lower rate of complete response. To address
this issue, over the last two decades the addition of either
chemotherapy or radiation sensitisers to RT has been explored to
improve local control. The evidence for these two treatment
options has been has been provided by two randomised trials: the
BC2001 trial showed an improvement in locoregional disease-free
survival with the addition of 5-ﬂuorouracil (5FU) and mitomycin C
to RT,86 and the BCON trial showed improved overall survival with
the addition of nicotinamide and carbogen (a gas mixture of 2%
carbon dioxide and 98% oxygen).87 The low recurrence rates
observed in these trials have led to growing acceptance that RT
with concomitant chemotherapy or radiation sensitisers is a valid
alternative to cystectomy for many patients, and led to NICE
recommending that either RT or surgery should be offered to
patients being treated with curative intent.88
LOWER GASTROINTESTINAL RT PRACTICE-CHANGING TRIALS
Radical surgical resection is the cornerstone of treatment for
localised rectal cancer; however, in the 1980s, radical surgery
alone resulted in unacceptably high rates of local recurrence.89
Signiﬁcant improvements in surgical techniques, such as total
mesorectal excision (TME), resulted in lower local recurrence rates
and led to a range of phase III trials that tested the additional
beneﬁt of pre-operative RT (Table 4).
Pre-operative RT in rectal cancer
Two phase III international trials demonstrated statistically
signiﬁcant reductions in local recurrence when 25 Gy in ﬁve
fractions was given prior to TME, compared with TME alone.90,91
There was no difference in overall survival. These trials changed
the standard of care for patients with resectable rectal cancer, with
clinical adoption initially occurring in Northern Europe; however,
this approach is now globally supported by international
guidelines.92
Investigating a different strategy, four phase III trials established
pre-operative concurrent chemoradiation as a standard of care
for locally advanced rectal cancer. Two of these trials
demonstrated that addition of concurrent 5FU and leucovorin to
RT (45 Gy in 25 fractions) signiﬁcantly reduced local recurrence,
with no difference in overall survival.93,94 Two additional phase IIIT
ab
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trials demonstrated reduced local recurrence and toxicity when
pre-operative chemoradiation was used, compared with post-
operative chemoradiation95,96 and this approach is supported in
both resectable and locally advanced rectal cancer. The use of pre-
operative chemoradiation is now supported by international
guidelines.97,98
With these two overlapping standards of care, two further
phase III trials were performed that directly compared the two
approaches.99,100 These trials reported no signiﬁcant difference in
local recurrence and survival, and as a result, both approaches are
supported by international guidelines. Chemoradiation is recom-
mended as the preferred option when the patient has locor-
egional disease with very close margins of surgical excision.
Anal cancer RT practice-changing trials
Three phase III trials performed in the 1980s resulted in a major
change in clinical practice.101–103 Prior to this, radical surgery was
performed that resulted in permanent colostomy. The trials
determined concurrent mitomycin C, ﬂuorouracil and RT as the
standard of care, resulting in the avoidance of major surgery in the
majority of patients. Subsequently the UK ACT2 trial introduced a
continuous shrinking-ﬁeld RT technique, using a lower total dose
(50.4 Gy) where initial wide ﬁeld irradiation was immediately
followed by boost radiotherapy targeting areas of visible cancer.
This approach was adopted into European practice and supported
in European guidelines.104 Three phase III trials (ACT2, RTOG 9811
and ACCORD 03) demonstrated that additional chemotherapy
either before or after concurrent chemoradiation did not improve
cancer outcomes.105–107 Furthermore, in the RTOG 9811 trial, pre-
operative and concurrent cisplatin-5FU led to higher colostomy
rates and inferior disease-free survival rates. In addition, two small
phase II trials had a signiﬁcant effect on clinical practice. The UK
EXTRA trial reported acceptable local control and toxicity using
concurrent capecitabine rather than 5FU,108 and the use of
concurrent capecitabine is now supported in international guide-
lines. The RTOG 0529 phase II trial109 reported an improvement in
acute toxicity and acceptable outcomes with IMRT, compared with
the RTOG 9811 trial, and IMRT is now widely used in anal cancer. It
is clear that practice-changing and practice-deﬁning clinical trials
are feasible in this rare cancer.
THERE IS SUBSTANTIAL INEQUALITY IN ACCESS TO EVIDENCE-
BASED RT
Clinical trials have some perceived disadvantages. One such
shortcoming is the length of time taken to produce mature results,
which is often many years; aspects of management potentially
become out-dated by the time the trial is able to report results.
Another disadvantage concerns the selective populations that are
often treated within trials, which may not represent ‘real life’
patients; patients in trials are typically younger and ﬁtter, have less
co-morbidities and are submitted to stricter follow-up schemes
than the general patient population.110 Both of these aspects can
limit uptake of trial results into clinical practice,111 and this may be
hampered further by infrastructural, organisational or ﬁnancial
barriers, such as those observed for twice-daily RT in treating
limited-stage SCLC.
The European SocieTy for Radiotherapy and Oncology-Health
Economics in Radiation Oncology (ESTRO-HERO) project surveyed
European countries regarding the availability of RT facilities and
personnel, which are key issues for RT access (Fig. 2). The study
reported large variation across Europe in resource availability, and
showed a clear correlation with national income. It also high-
lighted serious gaps in RT provision and stafﬁng that was more
pronounced in, although not limited to, countries in Southern and
Eastern Europe.112,113 Across 40 European countries, RT utilisation
was much lower than estimated; just under half were treating less
than 70% of patients requiring RT.114 Similarly, the Global TaskT
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Force on Radiotherapy in Cancer Care and Control (GTFRCC)
published a model of worldwide RT supply and demand based on
cancer incidence, number of RT machines available and evidence-
based guidelines for RT. At least 36 countries had no RT machines
at all, and there was a distinct correlation between national
income and availability of RT machines. Using available evidence
from world-wide clinical trials and guidelines, this report also
provided compelling evidence that investment in RT would save
many millions of life-years and also create positive economic
beneﬁts4,115; even if a patient is no longer able to contribute to the
workforce, the intrinsic personal or societal value of a life-saving
intervention has been estimated to be 2.3 times the gross
domestic product per person in a given year.116 In order to
achieve the ultimate goal of equal access to radiotherapy
worldwide, the GTFRCC has set forward a number of ‘Calls to
Action’, including measurable targets for expansion of human
resources and RT capacity (both requiring sustainable ﬁnancing),
aligning RT access with universal healthcare coverage and, last but
not least, systematically including radiotherapy expansion in
national cancer control planning.
RT treatment machinesa b
dc Medical physicists and
dosimetrists
Mean:5.3
0–2 2–4 4–6 6–8 >8
0–5 5–10 10–15 15–20 >20
0–5 5–10 10–15 15–20 >20
0–15 15–30 30–45 45–60 >60
Median:5.3 Min:1.4 Max:9.5 Max:30.9Min:2.5Mean:12.8 Median:11.0
Mean:9.8 Median:9.8 Min:0.0 Max:21.9 Max:78.0Min:4.9Mean:36.9 Median:30.9
Radiation therapy technicians
and nurses
Radiation oncologists
Fig. 2 Megavoltage RT equipment and personnel per million inhabitants across Europe. Countries coloured grey indicate no available data.
Reprinted from ref. 130. Copyright (2015), with permission from Elsevier
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How can the RT community tackle these issues?
Large-scale clinical trials have provided a solid rationale for
making changes in clinical practice to improve patient care;
adequate infrastructure and human resources are now needed
to enable the implementation of these changes globally.
International organisations are working to improve access to
RT and to encourage research. The International Atomic Energy
Agency (IAEA) has highlighted inequity in access to RT, and it
promotes the setting up and maintaining of RT services in low-
and middle-income countries through partnerships with centres
in high-income countries. ESTRO promotes evidence-based RT
and addresses the inequity of access to high-quality RT across
Europe. The newly established ESTRO Cancer Foundation aims
to raise awareness of RT beneﬁts and to create a community of
supporters. Its ﬁrst initiative is the Marie Curie Legacy Campaign
(www.150yearsmariecurie.org), which will educate the general
public about the life and work of this iconic scientist, and
highlight RT as a key component of cancer treatment (Fig. 3). In
addition, the UK Clinical and Translational Radiotherapy
Research Working Group (CTRad) facilitates the development
of new RT trials and raises awareness of the importance of RT
research to funding bodies. A particular success has been
through engagement with pharmaceutical companies to drive
forward research into RT and novel drug combinations.11 Both
ESTRO and CTRad are committed to tackling major challenges
for future RT trials and assisting stakeholders in developing
solutions (Table 5).
WHAT IS THE FUTURE OF RT RESEARCH?
Future RT research will focus on reducing treatment toxicity and
on further improving survival rates and management of locor-
egional relapse. This is likely to be increasingly driven by
biomarkers to assist in individualising RT treatment. There now
exist validated biomarkers for some cancer types, for example p16
positivity predicts better prognosis and response to chemoRT
treatment in head and neck cancer. However, for most cancer
types, biomarkers for response to RT treatment and toxicity are
not yet established, and this will be an important area of future
translational RT research. In this section, we discuss selected areas
of predicted future clinical RT research. As we look to further reﬁne
RT, our trial designs will also need to evolve accordingly.
Reducing the toxicity of RT
RT-related toxicity may be reduced by avoiding unnecessary
treatment and by continued improvements in tumour targeting,
to reduce the ‘safety margin’ of normal tissue around the cancer.
Technological developments such as proton beam therapy and
the integration of magnetic resonance imaging (MRI) technology
into RT are likely to be important areas of future research aiming
to improve tumour targeting.
Proton beam therapy has the potential to dramatically reduce
doses to nearby critical structures, because the physical properties
of the proton radiation beam are very different to photons. This is
especially important, for example, near the eye and parts of the
central nervous system. It also reduces the risks of ionising
radiation in paediatric patients, which can have devastating
effects on growth and development.117 Until now, proton beam
therapy has mainly been introduced in privately funded centres
rather than through comparative clinical trials, and thus the
evidence base for some tumour types is very limited. Small-scale
clinical trials and patient registries are now being established, and
it is hoped that the wider introduction of proton beam therapy on
a global scale will provide opportunities for larger international
clinical trials to demonstrate clinical beneﬁt and assess the cost-
effectiveness of this new therapy for a broad range of tumour
types.
MRI allows for greater resolution of soft tissue than CT, which
means many tumours, such as abdominopelvic cancers, can be
identiﬁed more accurately, meaning smaller normal tissue margins
are needed. MRI is currently widely used to improve the accuracy
of radiological tumour staging and to guide the contouring of
structures for RT planning, prior to treatment. The current
challenge concerns how to accurately identify and monitor these
tumours online during treatment. Many centres have the
capability to perform daily image guidance with repeat CT
scanning before each RT treatment, using the linear accelerator
itself; however, this is of limited use for accurately imaging soft
tissue, especially where there is considerable organ motion.
Recently, hybrid RT machines have been developed that combine
a linear accelerator with an MRI scanner (MR-linac) that is able to
perform a new generation of imaging before and during RT
delivery. This allows accurate localisation of the tumour pre-
treatment and supports the ability to adapt treatment daily if
required and to monitor the tumour and critical organ movement
during treatment.118,119 This, in the future, will allow ‘gating’; the
automatic switching on and off of the treatment beam according
to pre-set parameters, for example to allow for respiratory and
bowel motion. This may facilitate greatly improved image
guidance of RT delivery, minimising the dose to normal tissues
and enabling dose escalation to the tumour.
Assessment of these new technologies will be facilitated by the
recently published framework for evaluation of RT technology, R-
IDEAL,120 and by international clinical and research networks, for
example the European Particle Therapy Network (an ESTRO
taskforce) and the ATLANTIC MRL research consortium. Recently
funded clinical trials are increasingly including imaging, blood or
Fig. 3 Celebrating 150 years since the birth of Marie Curie.
Reproduced with permission from ACJC-Musée Curie
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tissue biomarkers, and we expect this will support a move towards
the increased personalisation of RT, for example identifying
which patients are likely to beneﬁt from RT and tailoring the
dose or fractionation. Trial designs that encompass biomarker
discovery or prospective validation of predictive biomarkers will
maximise value for trial funders and research opportunities for
patients.121,122
Improving survival rates with RT
Improved survival rates are likely to occur through employing/
adopting RT in novel situations. There is growing interest in using
SBRT to deliver a much higher dose than traditionally given for
oligometastatic or oligoprogressive disease123; early trials have
shown improvements in progression-free survival for this
approach.124 Larger trials aiming to evaluate the role and beneﬁt
of ‘radical’ high-dose RT in oligometastatic disease across disease
sites are currently underway in the UK (CORE) or in development
(ESTRO/EORTC OligoCare studies). SBRT and/or MR-guided RT may
also prove beneﬁcial in cancers not traditionally amenable to RT,
such as renal and pancreatic cancers, due to the previous inability
to irradiate without including large normal tissue margins that
precluded the delivery of a tumouricidal dose.
Survival may also be improved through dose escalation via
improved image guidance (as previously discussed), and novel
drug combinations with RT. There is currently particular interest in
combining RT with DNA damage response inhibitors and
immunotherapy. RT induces direct cell death by causing single-
and double-stranded DNA breaks. Double-stranded DNA breaks
are much more lethal to cells than single-strand breaks; however,
single-stranded DNA breaks are a more frequent consequence of
ionising radiation. DNA damage response inhibitors may therefore
act in a ‘synthetically lethal’ manner to selectively increase the
number of double-stranded DNA breaks in irradiated cells, with
minimal effects on nearby non-irradiated cells.125 RT also
promotes immune-mediated cell death through the increased
release of tumour antigens, the induction of inﬂammatory
cytokines, and the transient overexpression of cell surface
receptors.126 Together, these mechanisms facilitate effector T cell
killing of irradiated tumour cells and priming of antigen-
presenting cells to increase the adaptive immune response
against tumour cells elsewhere in the body, in non-irradiated
areas. There are multiple ongoing clinical trials of DNA damage
response inhibitors with RT127 and immunotherapy with RT.128,129
Efﬁcient trial design in this ﬁeld, through use of adaptive model-
based phase I dose-ﬁnding strategies, risk stratiﬁcation, biomar-
kers and/or appropriate intermediate endpoints, and multi-arm
multi-stage studies will support more rapid evaluation of the most
promising drug–RT combinations.
CONCLUSION
Major steps have been made in developing new RT techniques
and regimens to optimise cancer outcomes, whilst simultaneously
minimising toxicity. These have been achieved through high-
quality clinical trials, involving collaboration across countries.
Particular successes have been the introduction of SBRT for
early-stage NSCLC especially for medically inoperable patients,
and the increasing use of hypofractionation in breast and prostate
cancer as this improves convenience for patients and cost-
effectiveness for healthcare providers, whilst maintaining excellent
cancer outcomes. Despite these achievements, and together with
the high cost-effectiveness of RT, access to evidence-based RT is
not available to everyone. Organisations such as the IAEA, ESTRO
and CTRad are making great progress in raising awareness of this
inequity and educating both health professionals and policy
makers. As we mark the 150th anniversary of Marie Curie’s birth,
we hope that international co-operation of the RT community will
facilitate high-quality evidenced-based RT for the millions of
people who require it, regardless of where they live.
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